Early results from a phase 1 clinical trial of CAR T cells administered directly into the chest cavity for the treatment of pleural cancers has shown low toxicity and high efficacy.
New research has linked microsatellite instability and the number of insertion/deletion mutations present in a tumor to clinical response to checkpoint inhibition.
Early results from a small clinical trial of a new personalized cancer vaccine called NEO-PV-01 in advanced melanoma appear promising — and no significant toxicity issues have yet been revealed.
Many CML patients on TKI treatment report muscle complaints, but there has been little work to find out why. A new study sought to find out more about the nature of these complaints and to undercover a biological mechanism to explain them.
Organoids created from tumor samples have been revolutionizing laboratory research, but they also may begin helping oncologists decide on treatment regimens for patients.
Experts are calling for a protected drugs list to stop shortages that could impact the chance of survival for childhood cancer patients.
Could combining the oncolytic viral therapy TVEC with other therapies enhance the immunotherapy’s efficacy, allowing more patients to benefit?
Although patients with CML may not be eligible for TKI discontinuation based on transcript alone, the type of transcript seen may have some implications for loss of treatment remission.
Researchers identified 15 genes that they said independently predict the survival outcome of patients with kidney renal papillary cell carcinoma.
Researchers provide further proof that CRISPR can augment cancer treatment in the lab, but many barriers remain before clinical trials can be conducted in patients.
